ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

Statin Drugs For Alzheimer's Recognized as Emerging Indication

  [ 70 votes ]   [ Discuss This Article ]
www.ProHealth.com • September 23, 2004


MAYWOOD, N.J.--(BUSINESS WIRE)--Sept. 23, 2004--Nymox (NASDAQ:NYMX) Has Global Patent Rights to Use of Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

According to a new lead story in the September 13 2004 issue of Physician's Weekly, there is now considerable epidemiological evidence suggesting that statins, a class of widely prescribed cholesterol-lowering drugs, can reduce risk of Alzheimer's disease and possibly slow its progression. The story, "Statins: The Emerging Indications," outlines the encouraging evidence and notes that further large trials studying statins and Alzheimer's disease are now in progress.

Physician's Weekly is a weekly medical news publication widely distributed to major American hospitals and estimated to be read by over 200,000 physicians. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. "This promising development in Alzheimer's disease treatment has caught the attention of the medical community. One of the most appealing facts about this is that some of the astronomical costs in new drug development may be avoidable," said Dr. Michael Munzar, Medical Director of Nymox.

Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone. The potential for the use of statin drugs in reducing the risk of Alzheimer's disease has been featured extensively in the media such as New York Times (April 13, 2004), Fortune magazine (August 9, 2004), Newsweek magazine (Jan 19, 2004), The Los Angeles Times (June 22, 2003), and The Wall Street Journal (April 17 and 18, 2002).

Numerous scientific and clinical studies have explored the potential benefits of statin drugs to prevent or treat AD. Studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs. In addition of recent studies presented at major medical conferences, published peer-reviewed studies include, for example, International Journal of Geriatric Psychiatry 2004;19:327-32; Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Energy NADH™ 12.5mg Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Safely Burn Away Body Fat Safely Burn Away Body Fat

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map